(Q73286288)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126220%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Defining the ideal tumor marker for prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126220%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

J E Montie

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126220%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

S E Meyers

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126220%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 May 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126220%20AND%20SRC:MED&resulttype=core&format=json

Urologic Clinics of North America

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126220%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126220%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

247-252

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126220%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126220%20AND%20SRC:MED&resulttype=core&format=json

Dangers of using "optimal" cutpoints in the evaluation of prognostic factors

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

The American Joint Committee on Cancer. Criteria for prognostic factors and for an enhanced prognostic system.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

Prostate carcinoma: an autopsy evaluation of the influence of age, tumor grade, and therapy on tumor biology.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

AN " ACID " PHOSPHATASE OCCURRING IN THE SERUM OF PATIENTS WITH METASTASIZING CARCINOMA OF THE PROSTATE GLAND

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

The Effect of Radiation Therapy after Radical Prostatectomy in Patients with Elevated Prostate Specific Antigen Levels

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

Current prognostic factors for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

The Second Stanford Conference on International Standardization of Prostate Specific Antigen Assays

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

The clinical usefulness of prostate specific antigen: update 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: a trial with 10-ethyl-deaza-aminopterin

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

The results of radiotherapy for isolated elevation of serum PSA levels following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

Statistical aspects of prognostic factor studies in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970369-4

7 January 2021

10.1016/S0094-0143(05)70369-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126220%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference